Trusted Resource for Clinical Trials, Protocols & Progress
Open access to clinical trial data is a cornerstone of scientific integrity and public trust. In recent years, regulatory agencies, journal editors, and patient advocacy groups have increasingly emphasized the importance of making clinical trial data publicly available. Open data promotes reproducibility, allows secondary analyses, and exposes selective reporting or misconduct.
Click to read the full article.
As global regulations and journal policies increasingly demand open access to clinical trial data, researchers and sponsors must prepare datasets in formats suitable for public repositories. Improper or incomplete preparation can lead to regulatory delays, data misuse, or breaches of participant confidentiality. Therefore, data preparation is not just a technical step — it’s a regulatory, ethical, and scientific responsibility.
Click to read the full article.
As open data becomes a regulatory and ethical expectation in clinical research, selecting the right data repository is critical. A good repository ensures data security, metadata integrity, ease of access for researchers, and compliance with global transparency mandates. With numerous platforms available, sponsors and researchers must understand which repositories align with their data type, jurisdiction, and privacy standards.
Click to read the full article.
The demand for clinical trial transparency is at an all-time high, driven by global regulatory bodies, funding agencies, and public interest in research integrity. However, transparency must be balanced with a critical obligation: protecting the privacy and confidentiality of trial participants. The disclosure of sensitive health data, even inadvertently, can have lasting consequences for individuals and violate legal protections.
Click to read the full article.
Open access (OA) has moved from being an academic preference to a clinical trial mandate. Regulatory agencies, funding bodies, and public advocacy groups are demanding increased transparency and wider availability of trial data. At the center of this movement are journal publishers and study sponsors, whose open access policies shape how, when, and where clinical trial results are published and accessed.
Click to read the full article.
As clinical research increasingly adopts digital tools and open science policies, there is growing pressure to ensure that trial data is not only available but usable. This is where the FAIR principles—Findable, Accessible, Interoperable, and Reusable—come into play. These principles, first formalized in 2016, provide a structured approach to maximize the value of clinical data for stakeholders, regulators, and the public, without compromising patient privacy or regulatory compliance.
Click to read the full article.
In the era of open science and regulatory transparency, the need to make clinical trial data publicly available must be carefully balanced against the legal and ethical obligation to protect participant confidentiality. Anonymization of clinical data—the process of irreversibly removing personal identifiers from datasets—is essential for achieving this balance. Regulatory authorities such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and Health Canada all endorse or require data anonymization before trial data is shared or published.
Click to read the full article.
As part of its commitment to scientific transparency and research reproducibility, the U.S. National Institutes of Health (NIH) implemented a comprehensive Data Management and Sharing Policy (DMSP) in 2023. This policy requires all NIH-funded researchers to prospectively plan for, and subsequently share, scientific data generated from research, including clinical trials. The move underscores NIH’s strategic push towards open science and is expected to drive cultural and operational changes across academic and commercial research sectors.
Click to read the full article.
The call for transparency in clinical research has extended well beyond national regulations. In a globally connected research environment, collaborative efforts are essential to ensure uniform access to trial data, enhance trust, and promote scientific equity. From the WHO’s coordination through the International Clinical Trials Registry Platform (ICTRP) to joint efforts between the FDA and EMA, international collaboration is now central to data transparency policies and infrastructure.
Click to read the full article.
Individual-level data (ILD), also known as participant-level data, is considered the gold standard for secondary analyses, meta-analyses, and reproducibility of clinical trial results. Yet, sharing such granular datasets introduces significant legal, regulatory, and ethical complexities. While transparency is a scientific imperative, it must be balanced with the rights of trial participants, especially regarding confidentiality, consent, and re-identification risk.
Click to read the full article.
